Learn more about a pan-JAK inhibitor for the management of chronic hand eczema: insights from dermatologist Dr. Sonja Molin
ESC asked dermatologist and researcher Sonja Molin, MD, to share her expertise on the pan-JAK inhibitor Anzupgo® (delgocitinib) and how this medication is used to manage CHE.
What is Chronic Hand Eczema?
Chronic hand eczema (CHE) is an inflammatory skin condition that is distinct from other forms of eczema, as it primarily affects the hands. It is caused by the interplay of the skin barrier, an overactive immune system, and environmental factors.
It is estimated that it affects approximately 10-15% of the adult population and can have a profound impact on those living with the condition.
CHE is common among individuals who work with their hands and frequently wash them, as well as those whose hands are regularly exposed to chemicals. This includes professions such as nursing, healthcare, hairdressing, and mechanics. Additionally, CHE is more prevalent in individuals with atopic dermatitis (the most common form of eczema).
What are pan-JAK inhibitors?
Pan JAK inhibitors are a class of drugs that block Janus kinase (JAK) enzymes, which play a key role in immune signalling pathways. By inhibiting these enzymes, they help reduce inflammation and are used to treat conditions such as atopic dermatitis and CHE.
How does Anzupgo® work?
Anzupgo® is a cream that is applied directly to affected skin of the hands and wrists twice a day. However, patients should use this medication exactly as prescribed by their health care provider.1
Anzupgo® works by blocking Janus kinases, a group of enzymes that play an important role in the inflammatory process associated with CHE. By blocking these enzymes, the medication helps reduce inflammation, alleviating symptoms such as redness, itching, and dryness.
Who is Anzupgo® approved for?
Anzupgo® is indicated for adults with moderate to severe CHE who either cannot use topical corticosteroids or find them ineffective.
What are the side effects of this medication?
The most common side effects, although relatively uncommon, include skin irritation like burning and/or stinging at the site where the medication is applied.
All medications have risks and benefits, and the details of the risks and benefits should be reviewed with the prescribing health care provider.
What if my CHE does not get better?
If you find your CHE isn’t responding to treatment, let your doctor know, as your treatment plan may need to be adjusted. A qualified health care professional, such as a dermatologist, can help reassess your or your child’s condition and recommend alternative therapies. There is no cure for CHE, but patients can achieve excellent control and live quite comfortably with existing medication.
Eczema Society of Canada thanks Sonja Molin, MD, for her volunteer contribution to this educational content.
Reference: 1 LEO Pharma Inc. (August 2025). Anzupgo® (delgocitinib) [Product Monograph], Topical Janus Kinase (JAK) Inhibitor.
Disclaimer: Information provided in this resource does not constitute medical advice and is not intended to be used as a diagnostic tool. The information is up-to-date at time of publication. All medications, interventions, and treatment plans have risks and benefits, and it is important that individuals discuss their or their child’s specific health care needs with a qualified health care professional.
